Corransac, France

Francedillaoise Couret

This inventor holds 1 USPTO granted patent. Top assignee: Pierre Fabre Medicament. Active years: 1999.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Francedillaoise Couret: Innovator in Triazine Derivatives

Introduction

Francedillaoise Couret is a notable inventor based in Corransac, France. He has made significant contributions to the field of chemistry, particularly in the development of triazine derivatives. His innovative work has led to the filing of a patent that showcases his expertise and creativity.

Latest Patents

Francedillaoise Couret holds a patent for "3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives." This invention highlights his ability to create novel compounds that may have various applications in pharmaceuticals and other industries. His patent portfolio includes 1 patent, reflecting his focused approach to innovation.

Career Highlights

Couret is currently employed at Pierre Fabre Medicament, a prominent company in the pharmaceutical sector. His role at the company allows him to work on cutting-edge research and development projects, contributing to advancements in medical science. His dedication to his work has positioned him as a valuable asset in his field.

Collaborations

Throughout his career, Francedillaoise Couret has collaborated with esteemed colleagues, including Elisabeth Dupont-Passelaigue and Jean-Francedillaois Patoiseau. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Francedillaoise Couret is a distinguished inventor whose work in triazine derivatives exemplifies innovation in the pharmaceutical industry. His contributions, along with his collaborations, continue to influence the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…